Podcasts about biomarkers

Yes, it's really called that, and yes, it comes from the same word you're thinking of. Spermidine is becoming bigger and bigger in the longevity world, and for good reason.Today, Kyle's breaking down what spermidine actually is, why researchers are excited about its link to a cellular "clean-up" process called autophagy, whether it's connected to Japan's remarkably high number of centenarians, and which everyday foods (yes, including one very sticky Japanese staple) are the richest natural sources. Plus: is the supplement version worth trying, or is food still your best bet?In this episode:What spermidine is The autophagy connection: your body's cellular clean-up crew, and how spermidine may support it (without replacing fasting)Why natural spermidine levels decline with age, and what that might mean for healthy agingWhat the actual human research shows so far, including a small BDNF study and a larger observational trial, and where the evidence is still thinThe best natural food sources of spermidine (natto, wheat germ, mushrooms, legumes, aged cheese), for people who will never touch a supplementKyle's honest take on spermidine supplements, and why his current stance is "food first, supplement curious"Today's feelgood thing: the small, smug joy of being rightStudies mentioned:Nutraland rice germ extract pilot study coverageLongitudinal association of dietary spermidine with hepatic function indexes and cardiometabolic traits (European Journal of Nutrition)Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults (JAMA Network Open)New here? feelgoodery is your weekly space for feeling good without pretending everything's fine -  nutrition, mindset, and real strategies for showing up for yourself, hosted by Kyle Buchanan (Broadcaster, Speaker, Certified Nutritional Practitioner, Resident Wellness Contributor on Canada's The Morning Show & host of The Exhale on SiriusXM), and his live-studio dog Sam.Disclaimer: This podcast is for informational purposes only and isn't a substitute for professional medical advice. Please always consult with your health care provider.Follow along: Instagram @itskyleb | New episodes weekly

In this episode of Living Well with MS -- where we explore topics relating to living a full and healthy life with multiple sclerosis -- we are pleased to welcome Brett Drummond and Karen Campbell. Brett is from MSTranslate and hosts the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) patient day and podcast. Karen is a nurse and MS researcher who lives with MS and attended the conference this year. Watch this episode on YouTube. Keep reading for the topics, timestamps, and our guest's bio. 00:00 Introduction to ECTRIMS 2025 and Speakers 02:02 Overview of ECTRIMS Conference Highlights 02:41 Brett's Insights on MS Research 09:07 Emerging Treatments and Therapies for MS 15:10 The Role of Viruses in MS 18:28 Lifestyle Modifications and Rehabilitation in MS 20:03 Biomarkers and Their Importance in MS 24:24 Engaging the MS Community in Research 28:24 Karen's Perspective as a Patient and Researcher 33:55 Q&A Session: Addressing Community Questions Watch the original presentation here Connect with Ciara on LinkedIn New to Overcoming MS? Learn why lifestyle matters in MS - begin your journey at our 'Get started' page Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out: Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS here. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us: If you enjoy this podcast and want to help us continue creating future podcasts, please leave a donation here. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. If you like Living Well with MS, please leave a 5-star review.

In this episode of JCO Precision Oncology Article Insights, host Jiasen He summarizes the article, "Beyond the Brain: Circulating Tumor Cells as a Tool for Diagnosis and Monitoring," by Lessi and colleagues. LINK TO FULL TRANSCRIPT

Mike Lustgarten holds a PhD in physiology and spent years as a research scientist at the Tufts Human Nutrition Research Center on Aging, studying gut microbiome composition and blood metabolomics in older adults. In mid-2025 he left academia to go full-time with his platform, Conquer Aging or Die Trying. Since 2015 he's tested his blood 8 times per year, runs 25+ microbiome panels, 20+ epigenetic tests, and logs the weight of every food he eats to correlate diet changes directly against biomarker movement.He asked for blood tests more than once a year. His doctor wrote "suffers from anxiety" in his medical record.→ Lipoprotein A: doctors say "measure it once, it's genetic." He's run 50 tests since 2015 and moved his average from peaks of 145 nanomolar down to 88, with some tests approaching 70. The recipe matters. The data says so→ HDL was 28mg/dL on a high-carb bodybuilding diet. Now consistently 50 to 69mg/dL for 18 tests in a row, inside his self-defined optimal range. Four dietary variables explain 81% of the variability. Identified entirely through his own correlations→ Eating 200g of sardines per day may have raised his homocysteine from 8 to 12 micromolar in a single test period. The proposed mechanism: inorganic arsenic in sardines requires methylation to be excreted, depleting adenosylmethionine and disrupting homocysteine metabolism. He's now switched to salmon to test the hypothesis→ On Brian Johnson, biohacking as a term, DHEA sulfate declining despite optimal testosterone, and why "analysis by paralysis" is the real risk of wearables: all covered, without pulling punchesIf your GP told you your labs are fine and you still don't feel fine, this episode is the argument for why "within reference range" and "optimal" are not the same thing.

Can you actually extend your life without sacrificing your quality of life? Ethan sits down with Dr. Florence Comite, a pioneering physician in precision medicine and longevity, to explore what really drives healthy aging. They discuss metabolic health, genetics, hormones, biomarkers, muscle, diabetes, GLP-1 medications, and why individual health data matters more than one-size-fits-all advice. Ethan also shares his own journey of losing 300 pounds, navigating different diets, and learning how to maintain his weight. Dr. Comite explains why understanding your personal biology can help you make better decisions about your health and future.Subscribe to Ethan's newsletter:https://ethansuplee.substack.com/subscribeSHOW HIGHLIGHTS00:00 - What Does Longevity Really Mean?03:00 - Living Longer vs. Living Better06:00 - Why Diets Don't Work for Everyone09:00 - Genetics, Biomarkers and Small Habits12:00 - Women's Hormones and Menopause15:00 - Testosterone, Aging and Men's Health18:00 - Why GLP-1 Medications Matter21:00 - GLP-1s and the Future of Metabolic Health24:00 - Understanding Blood Sugar and A1C27:00 - Managing Type 1 Diabetes30:00 - The Limits of Modern Medicine33:00 - How Ethan Lost 300 Pounds36:00 - Weight Loss, Maintenance and Diet Breaks39:00 - Testosterone, Muscle and Five Key Biomarkers42:00 - When Dieting Goes Too Far45:00 - Should Everyone Take a GLP-1?48:00 - Exercise, Addiction and Finding Balance Hosted on Acast. See acast.com/privacy for more information.

In this episode, Lorenzo Barba speaks with Henrik Zetterberg and Gemma Salvadó about the role of biomarkers in translational neurology and monitoring therapeutic efficacy.

HOST:  Hildy Grossman    CO-HOST:  Jordan Rich GUESTS:   Melina Marmarelis, MD    What if the secret to defeating lung cancer is already hidden inside our own cells? In this episode of Backstage @ Upstage, we explore the cutting edge of cancer care and how tiny biological clues are completely revolutionizing how we detect, understand, and treat lung cancer. We are joined by Dr. Melina Marmarelis, a leading thoracic oncologist and researcher at Penn Medicine (University of Pennsylvania). Dr. Marmarelis breaks down the vital role of biomarker testing and introduces us to the future of precision medicine: Next-Generation Sequencing. Discover how oncology is moving away from traditional, “one-size-fits-all” therapies toward hyper-customized treatment plans tailored to every individual patient—and how Artificial Intelligence is stepping in to analyze massive amounts of complex medical data to make it all possible. Tune in to discover the future of biomarker testing and how science, technology, and precision medicine are changing the outlook of lung cancer care to come!

What actually happens to skin when your hormones change? In this unfiltered episode, we sit down with powerhouse (twin!!) sisters Dr. Florence Comite, Yale & NIH-trained endocrinologist and author of the NY Times Bestseller: Invincible: Defy Your Genetic Destiny to Live Better, Longer and board-certified dermatologist Dr. Harriet Comite to connect the dots between hormones, endocrinology and skin health.You'll hear about:The perimenopause skin shift: Why fluctuating estrogen and plunging testosterone wreck your skin pH, leaving your barrier and microbiome vulnerable to skin chaos.Defying your genetic destiny: Dr. Florence breaks down her longevity playbook for rewriting your health span through epigenetics, deep sleep, and tracking the right biomarkers before stuff hits the fan.Acne & barrier health: Why adult breakouts demand serious intervention and why your basic bar soap belongs nowhere near your face.Peptides & GLP-1s demystified: The systemic reality of GLP-1 weight loss, rapid volume loss, and what actually happens when Silicon Valley bro-stacks BPC-157 and GHK-Cu ("the glow injection").Topical estrogen myth vs. reality: The science behind applying prescription estrogen cream on your face versus what systemic Menopause Hormone Therapy (MHT) actually delivers.Biomarkers you cannot ignore: The five metabolic markers that Dr. Florence says you need to know now to empower your future healthSun protection & vitamin D: The critical breakdown between UVA and UVB damage, and why your daily mineral SPF 50+ needs a serious oral vitamin D3/K2 backup.Disclaimer: Please note the discussion in today's podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or qualified healthcare provider with any questions you may have regarding a medical condition.Shop everything mentioned in this video here: https://shopmy.us/collections/7775269Invincible: Defy Your Genetic Destiny To Live Better, Longer (AMAZON USA): https://go.shopmy.us/p-88398576Invincible: Defy Your Genetic Destiny To Live Better, Longer (AMAZON CA): https://go.shopmy.us/p-88398633Oura Ring (AMAZON CA): https://go.shopmy.us/p-88399550AMAZON USA | Oura Ring: https://go.shopmy.us/p-88399608STELO - Wearable Glucose Biosensor: https://go.shopmy.us/p-88399636ABBOTT - Lingo CGM Biosensor: https://go.shopmy.us/p-88400306CYMBIOTIKA | Liposomal Vitamin D3 + K2 + CoQ10 Tangerine Dietary Supplement: https://go.shopmy.us/p-88400760Advanced Skincare by Harriet Comite MD | Sheer Physical Sunscreen Cream SPF 50: https://go.shopmy.us/p-88401014PROMO CODES: When you support our sponsors, you support the creation of Breaking Beauty Podcast! OneSkinBorn from over 10 years of longevity research, OneSkin is helping you unlock your healthiest skin now and as you age. For a limited time, try OneSkin with 15% off using code BREAKINGBEAUTY at oneskin.co/BREAKINGBEAUTY. After you purchase, they'll ask you where you heard about them. PLEASE support our show and tell them we sent youOseaClean, seaweed-powered skincare from the sea. Go to OSEAMalibu.com and get 10% off your first order with code BEAUTY. NutrafolSee thicker, stronger, faster-growing hair with less shedding in just 3–6 months. Right now, Nutrafol is offering our listeners $10 off your first month's subscription and free shipping when you visit Nutrafol.com and enter promo code BREAKING. CoyuchiCoyuchi is everyday luxury you can feel good about bringing into your home. Visit coyuchi.com/breakingbeauty for 15% off your first purchase of the most comfortable bedding you'll ever own. Some exclusions applyWacoalSupport for every you. Underneath it all, lies Wacoal. Visit WACOAL.com and use code BEAUTY at checkout for 10% off your first purchase. Offer valid for new customers only. Limit one code per customer.

AI isn't just writing emails and generating pictures anymore - it's starting to design the molecules that go into our bodies. In this special episode of Disconnected, we sit down with young scientist Jay Wang to explore how generative AI is helping create new proteins, accelerate drug discovery, and whether we should be concerned about bioweapon risks and health inequality.We also end the episode with a wonderfully weird look into the emerging world of AI that tries to open up two-way communications with whales, cows, and maybe even your dog.This episode of Disconnected covers:AI in Drug Discovery and Synthetic BiologyThe New Bottlenecks in MedicineDual-Use and Biosecurity RisksHealth Data, Inequality, and SurveillanceDecoding Animal Communication with AIJag Sharma: https://www.linkedin.com/in/jagsharmahttps://www.instagram.com/jagsharma/Jen Campbell:https://www.linkedin.com/in/jennifer-m-campbell/Jason Kapadia:https://www.linkedin.com/in/jasonkapadia/https://www.instagram.com/jasonkapadia/Felina Tan:https://www.linkedin.com/in/felinagabrielletan/Matt Webster:https://www.linkedin.com/in/mattwwebster/

Advance early Alzheimer's diagnosis: Master the appropriate use and interpretation of blood-based biomarkers in part 3 of this live masterclass. Credit available for this activity expires: 9/21/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/alzheimers-disease-precision-diagnostics-3-part-live-2026a1000xvy?ecd=bdc_podcast_libsyn_mscpedu

Blood-based Biomarkers, Anti-Amyloid Therapies and BeyondWe have another classic episode for you. From blood-based biomarkers to anti-amyloid treatments, join us as we explore the latest in Alzheimer's disease diagnosis and treatment with Dr. Halima Amjad. This episode will equip you to guide your patients about the latest Alzheimer's diagnostics as well as eligibility, risks and monitoring for anti-amyloid therapies.Claim CME for this episode at curbsiders.vcuhealth.org!Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CMEShow Segments Intro Case Cognitive and functional history reminders Diagnosing Alzheimer's Disease Blood-based biomarkers Anti-amyloid therapy indications, eligibility and contraindications Patient counseling and treatment decisions ARIA Key takeaways Outro Credits Written and Produced by: Natalie Barrett DO, Rachel K Miller MD Show notes, cover art and infographic: Natalie Barrett DO, Rachel K Miller MD, Leah Witt MD Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Sai S Achi MD, MBA,FACP Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Halima Amjad, MD DisclosuresDr. Amjad reports financial relationships with Centene (Advisor) and Craniometrix (Advisor). Relationships have not ended. The Curbsiders report no relevant financial disclosures. The production of this episode was supported by the Penn Geriatrics AGE-SMART Geriatric Workforce Enhancement Grant. This podcast content is solely the responsibility of the authors and does not necessarily represent the official views of the Health Resources and Services Administration or the U.S. Department of Health and Human Services. Sponsor: DocUpdateDownload DocUpdate today, free on the Apple App Store and Google Play Store.Sponsor: FIGSCurbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX. Sponsor: Continuing Education CompanyVisit CMEmeeting.org/curbsiders and use promo code Curb30 for 30% off all online courses and webcasts.Sponsor: Freedhttps://www.getfreed.ai/

Could Lyme disease and other chronic inflammatory triggers play a role in Alzheimer's disease—and could addressing those underlying factors change measurable Alzheimer's biomarkers? In this episode of the Tick Boot Camp Podcast, Dr. Richard Horowitz returns to discuss a provocative new case report he published exploring the relationship between Lyme disease, neuroinflammation, Alzheimer's disease biomarkers, and dapsone combination therapy. The conversation centers on a patient with a long history of Lyme disease who had an elevated phosphorylated tau 217 (p-tau217) level, an increasingly important blood biomarker associated with Alzheimer's disease. After completing a nine-week dapsone combination protocol, the patient's p-tau217 declined by approximately 63% and returned to the normal range. Her amyloid-beta 42/40 ratio also moved in a favorable direction, and she reported improved cognitive clarity. This case provides a new research question: Could infections, toxins, metabolic dysfunction, sleep disorders, microbiome disturbances, and other inflammatory drivers contribute to Alzheimer's pathology in subsets of patients—and could identifying and addressing those drivers change the course of the disease? Read the Published Study Read Dr. Horowitz's published study on SAGE Journals The case report provides the scientific foundation for much of the discussion in this episode, including the changes in p-tau217 and amyloid biomarkers following treatment. In This Episode, You'll Learn Lyme Disease and Alzheimer's Disease Dr. Horowitz reviews research that has investigated possible relationships between Borrelia burgdorferi, neuroinflammation, amyloid, phosphorylated tau, and Alzheimer's pathology. Much of the earlier work examining spirochetes and Alzheimer's disease involved brain tissue and postmortem studies. Dr. Horowitz explains why he believes studying Alzheimer's biomarkers in living Lyme disease patients may provide another way to investigate these questions. The discussion also explores an important distinction: finding an association between infection and Alzheimer's pathology does not mean every case of Alzheimer's disease is caused by Lyme disease. The Patient Who Sparked the New Case Report Dr. Horowitz describes a longtime patient with Lyme disease whose p-tau217 was substantially elevated despite her perception that her cognition was relatively good. After the patient underwent his nine-week dapsone combination protocol, repeat testing showed a substantial reduction in p-tau217, bringing the biomarker into the normal range. Dr. Horowitz also discusses changes in the patient's amyloid-beta 42/40 ratio, rheumatoid factor, and subjective cognitive function. The case led him to ask whether treatment directed at persistent infection and inflammation could influence biomarkers normally associated with Alzheimer's disease. What Is p-Tau217? A major portion of the interview focuses on the emerging use of blood-based biomarkers for evaluating Alzheimer's pathology. Dr. Horowitz discusses four primary biomarkers: p-tau217 – phosphorylated tau 217 p-tau181 – phosphorylated tau 181 Amyloid-beta 42/40 ratio Neurofilament light chain (NfL) He also discusses GFAP (glial fibrillary acidic protein) and the potential relevance of APOE genetics. Dr. Horowitz describes p-tau217 as one of the most sensitive and specific currently available blood biomarkers associated with Alzheimer's disease pathology. Amyloid May Be More Than Just “Plaque” Why does amyloid accumulate in the brain in the first place? The episode explores the concept of amyloid-beta as an antimicrobial peptide and the hypothesis that amyloid production may, in some circumstances, be part of the brain's response to biological threats. Dr. Horowitz discusses research examining potential infectious and environmental contributors to amyloid production, including: Borrelia and other bacteria Viral infections Fungal organisms Other microbes Environmental toxins The conversation then explores how a response that may initially be protective could potentially become harmful when amyloid accumulates and interferes with normal neuronal function. Amyloid, Tau and Neurodegeneration Dr. Horowitz breaks down two major features associated with Alzheimer's disease. Amyloid-beta plaques accumulate outside neurons and are associated with disrupted communication between brain cells. Tau proteins normally help stabilize structures inside neurons. Abnormally phosphorylated tau can become associated with neuronal dysfunction and neurodegeneration. The discussion also explores why some patients may have abnormal tau biomarkers without corresponding abnormalities in amyloid markers—and why much more research is needed to understand these patterns in people with chronic Lyme disease. Dapsone Combination Therapy and Cognitive Symptoms Dapsone has been a major focus of Dr. Horowitz's research into persistent Lyme disease. In this episode, he explains that his protocols involve combination therapy rather than dapsone alone and discusses his previous published work examining dapsone combination therapy in patients with persistent Lyme disease symptoms. According to Dr. Horowitz, improvements in memory, concentration, cognition, and word-finding difficulties have repeatedly been among the most notable improvements reported in his patient cohorts. He believes this observation deserves greater attention now that blood-based Alzheimer's biomarkers make it possible to investigate biological changes alongside cognitive symptoms. Dapsone, the Brain and the NLRP3 Inflammasome The discussion goes beyond dapsone's antimicrobial activity. Dr. Horowitz explains his interest in the NLRP3 inflammasome, an inflammatory pathway implicated in neuroinflammation and studied in relation to Alzheimer's disease. He proposes that dapsone could potentially have more than one relevant effect—targeting certain microorganisms as part of combination therapy while also influencing inflammatory pathways. This remains an area requiring further clinical investigation. Alzheimer's Disease May Have Multiple Drivers One of the most important themes of the interview is that Alzheimer's disease is unlikely to have a single universal cause. Dr. Horowitz applies his 16-point MSIDS (Multiple Systemic Infectious Disease Syndrome) model to cognitive decline and Alzheimer's disease. Potential contributors discussed include: Lyme disease and other infections Mold and mycotoxin exposure Heavy metals and environmental toxins Chronic inflammation Insulin resistance and blood sugar dysregulation Sleep disorders and sleep apnea Gut microbiome dysfunction Nutritional deficiencies Mitochondrial dysfunction Cardiovascular and metabolic factors Other sources of systemic inflammation Rather than focusing exclusively on amyloid or tau, Dr. Horowitz argues for investigating what may be driving those abnormalities in an individual patient. Lyme Disease Is Not the Only Possible Infectious Trigger The episode also examines the broader question of infection and neurodegeneration. Dr. Horowitz discusses scientific literature investigating organisms and infections beyond Borrelia, including Chlamydia pneumoniae, Helicobacter pylori, Coxiella burnetii, herpesviruses, and other microbial exposures. His central argument is not that every Alzheimer's patient has an infection. Instead, he believes clinicians and researchers should investigate whether infectious, toxic, metabolic, environmental, and inflammatory factors may coexist and contribute differently from patient to patient. The Challenge of Lyme Disease Testing The conversation also addresses limitations surrounding Lyme disease diagnostics. A negative standard Lyme disease test does not necessarily answer every clinical question surrounding prior exposure or persistent symptoms. The hosts and Dr. Horowitz discuss why testing methodology, timing, immune response, strain diversity, clinical history, and other factors may need to be considered when evaluating a complex patient. Dr. Horowitz also explains how he combines laboratory findings with clinical history and his MSIDS framework when evaluating patients. Why More Data Is Critical A single case can generate a hypothesis. It cannot establish a treatment standard. Dr. Horowitz repeatedly emphasizes the need for: Additional documented cases Standardized biomarker testing Long-term patient follow-up Larger patient cohorts Collaboration among Lyme-literate physicians and neurologists Shared research databases Multicenter studies Randomized controlled clinical trials The episode explores the possibility of physicians systematically collecting Alzheimer's biomarkers before and after treatment of specific MSIDS factors to determine which interventions, if any, consistently change those biomarkers. That type of data could help researchers move beyond individual clinical observations toward testable conclusions. Could Patient Data Accelerate Lyme and Alzheimer's Research? Matt and Dr. Horowitz discuss the potential for a secure research repository where physicians could contribute standardized patient data. For example, researchers could track a patient's infections, mold exposure, metabolic factors and other MSIDS variables alongside p-tau217, p-tau181, amyloid-beta 42/40 and NfL measurements. Repeating those measurements after individual interventions could help researchers identify patterns that would otherwise take years to discover through isolated clinical practices. Dr. Horowitz Is Developing an MSIDS App Dr. Horowitz also shares a major project currently in development. He says he is working with researchers from the University of California, Irvine on an application designed to translate his MSIDS framework into a digital tool. The goal is for users to enter information based on the MSIDS questionnaire and other health data, allowing the software to help guide them through the framework. Dr. Horowitz also discusses how a sufficiently large and secure database could eventually create opportunities for collecting real-world patient data and generating new research hypotheses. Lifestyle, Metabolic Health and Brain Health Not every potential driver discussed in this episode is infectious. Dr. Horowitz highlights several established areas of brain-health research, including: Mediterranean/MIND-style dietary patterns Regular physical activity Healthy blood sugar and insulin regulation Cardiovascular health Adequate sleep Addressing sleep apnea Omega-3 fatty acids Nutritional status Gut and microbiome health This reinforces one of the episode's central messages: cognitive decline may result from multiple interacting biological pressures rather than one isolated mechanism. Ending Chronic Illness The discussion also previews Dr. Horowitz's upcoming book, Ending Chronic Illness, scheduled for publication on October 13, 2026. The book expands on his 16-point MSIDS model and explores how overlapping infectious, inflammatory, environmental, metabolic, immune, neurological, and lifestyle factors may contribute to chronic disease. A separate Tick Boot Camp interview dedicated to the new book will be released this fall. Learn More About Dr. Richard Horowitz Dr. Richard Horowitz is one of the best-known physicians in the Lyme disease community and has spent decades treating patients with Lyme disease, tick-borne infections, and complex chronic illness. Tick Boot Camp has interviewed Dr. Horowitz multiple times about Lyme disease, Babesia, Bartonella, dapsone combination therapy, MSIDS, chronic inflammation, and emerging research. Visit Dr. Richard Horowitz's Tick Boot Camp page for all of our interviews, articles, and resources Additional Resources Explore all Tick Boot Camp interviews and information Key Topics Richard Horowitz, MD; Lyme disease; Alzheimer's disease; Alzheimer's biomarkers; Lyme disease and Alzheimer's; Lyme disease and dementia; cognitive decline; neuroinflammation; p-tau217; p-tau181; phosphorylated tau; amyloid beta; amyloid-beta 42/40 ratio; neurofilament light chain; NfL; GFAP; APOE4; Borrelia burgdorferi; chronic Lyme disease; persistent Lyme disease; dapsone; dapsone combination therapy; MSIDS; Multiple Systemic Infectious Disease Syndrome; biofilms; persister bacteria; brain inflammation; memory problems; brain fog; cognitive dysfunction; mold toxicity; mycotoxins; microbiome; infections and Alzheimer's disease; tick-borne disease; Lyme disease research; dementia research; Alzheimer's research.

Send us Fan MailWe normally think of a CT scan as a picture that a doctor looks at. But what if that picture is actually an enormous dataset containing thousands of quantitative measurements about what's happening inside your body? And what if AI could extract information from those images that humans simply can't measure by looking at them? Today we're going to explore how that could change not only how we diagnose disease, but how we develop new drugs.Dr. Susan Wood, Ph.D. ( https://vidalung.ai/ ) is President and CEO of VIDA Intelligence, a company focused on AI and quantitative imaging for pulmonary disease and clinical drug development.Dr. Wood has spent more than 25 years bringing innovative clinical technologies from concept to commercialization. But her connection to this field goes all the way back to her doctoral research at the Johns Hopkins Medical Institutions, where she combined measurements of three-dimensional lung structure with changes in lung function using high-resolution CT imaging.Dr. Wood holds a Ph.D. from Johns Hopkins, a Master's degree in Biomedical Engineering from Duke University, and a Bachelor's degree in Engineering from the University of Maryland.Before founding and leading VIDA, Dr. Wood held senior leadership positions at companies including R2 Technology and Vital Images, and she has served on the boards of several companies working at the intersection of medical imaging, AI and healthcare technology.At VIDA, Dr. Wood has spent more than a decade working to transform imaging into quantitative, clinically meaningful data that can be used in research and clinical trials.So today we're going to talk about a pretty fundamental question:What happens when we stop thinking of a CT or MRI as simply an image - and start thinking of it as a biological dataset?And perhaps even more importantly, could AI-powered imaging ultimately change how we discover, test and develop new drugs?#AI #ArtificialIntelligence #MedicalAI #MedicalImaging #CTScan #LungDisease #COPD #Pulmonology #DigitalBiomarkers #Biomarkers #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #HealthTech #Radiology #LungHealth #Pharma #AIMedicine #VIDAIntelligenceSupport the show

A young girl develops progressive neurological symptoms and a biomarker profile pointing strongly towards a particular metabolic disorder. There's just one problem: the genetic testing is negative. In this Metabolic Mystery, Dr Ayca Burcu Kahraman follows the clues beyond conventional DNA testing to finally crack the case. Can you solve it before she does? Read the paper: https://doi.org/10.1055/a-2903-9323

Endometrial cancer care is increasingly shaped by molecular information, making biomarker testing an essential part of treatment planning for patients with advanced or recurrent disease. In this episode of Inside the Lab, host Dr. Ali Brown, CEO of the American Society for Clinical Pathology, speaks with Dr. Casey Cosgrove, a gynecologic oncologist at The Ohio State University, and Dr. Meg Dibbern, a breast and gynecologic pathologist at Emory University, about how biomarkers including MMR/MSI, POLE, p53, and HER2 can help define tumor biology, inform prognosis, and guide systemic treatment decisions.  The guests explore how testing across immunohistochemistry, PCR, and next-generation sequencing fits into real-world laboratory workflows and how pathology and oncology teams can work together to ensure results are comprehensive, timely, and actionable. The discussion also considers the challenges of translating evolving clinical guidelines into practice and the importance of communication between the laboratory, clinicians, and patients as treatment options continue to expand. To claim credit for listening to this episode, please click here.

While biomarkers offer significant clinical promise by enabling earlier diagnoses, personalized therapies, and objective disease monitoring, they often fail to correlate with meaningful patient-centered outcomes such as quality of life and long-term survival. This disconnect is particularly stark in psychology and psychiatry, where complex conditions lack definitive biological signatures and risk being over-medicalized by surrogate metrics. Furthermore, practical challenges—including high costs, accessibility disparities, and the risk of false positives leading to unnecessary interventions—demand substantial caution. Ultimately, the script argues that biomarkers should be treated as fallible diagnostic adjuncts guided by intellectual humility and comprehensive clinical judgment rather than definitive stand-ins for patient health.

Dominik hat sein EGYM-BioAge ermittelt – doch was sagt diese Zahl über seine Gesundheit aus? Wir erklären, was hinter dem biologischen Alter steckt und wie Studiogeräte, Wearables und epigenetische Tests zu ihren Ergebnissen kommen. Wie zuverlässig sind diese Werte? Können Training und Ernährung unsere biologische Uhr beeinflussen? Und wann motiviert ein Alterswert zu gesunden Gewohnheiten, wann führt er in die Irre? ------------------------------------------------------------------------ Dominiks Buch zur pflanzenbasierten Sporternährung im UTB-Verlag: https://www.utb.de/doi/book/10.36198/9783838560328 Dominiks Gesundheitscommunity: www.gsundes-hannover.de Dominiks Online-Knie-Kurs: https://gsundes-hannover.de/knieschmerzen/ Dominiks Online-Rücken-Kurs: https://copecart.com/products/34bd5abb/checkout Marcs veganes Online-Fitness-Coaching: https://vegainer-academy.com/ Marcs Online-Kurs: https://www.copecart.com/products/a50f88f2/checkout ------------------------------------------------------------------------ Werbung: Dieser Podcast wird unterstützt von der Firma Watson Nutrition. Die Firma bietet als einzige umfassend laborgeprüfte Nahrungsergänzungsmittel für eine optimierte Nährstoffversorgung. Zum Angebot zählen Multi-Supplemente, Mono-Supplemente, Sportsupplemente wie Kreatin oder auch Proteinriegel, Shakes und essenzielle Aminosäuren Mit dem Code veganperformance erhältst du 5 % Rabatt auf deine Bestellung.  Zur Firmenwebseite: Watson Nutrition ------------------------------------------------------------------------ Kapitelmarken: 00:00:00 Intro: Biologisches Alter auf dem Prüfstand 00:00:52 Dominiks BioAge: Von 39 auf 24 Jahre 00:05:44 Fitness früher und heute: Leistung, Alltag und Wohlbefinden 00:11:48 Was bedeutet biologisches Alter überhaupt? 00:15:46 Körperliche Tests: Kraft, Beweglichkeit und Stoffwechsel 00:18:55 Blutwerte, Telomere und epigenetische Tests 00:22:41 Smartwatches, Ringe und Waagen: Welche Werte liefern sie? 00:27:55 EGYM BioAge: Wie entsteht die Alterszahl? 00:31:51 Neue Algorithmen: Wie vergleichbar bleiben die Ergebnisse? 00:33:09 Werbung: Watson Nutrition 00:34:18 Biologisches Alter senken: Was zeigen die Studien? 00:42:18 Vegane Ernährung und Altern: Die Zwillingsstudie 00:48:53 Vorteile: Motivation und sichtbare Fortschritte 00:53:08 Nachteile: Stress und Selbstoptimierungsdruck 01:00:22 Messgenauigkeit, Scheinsicherheit und Marketing 01:06:07 Fazit: Was für ein gesundes Leben wirklich zählt ------------------------------------------------------------------------ Quellen: Belsky, D. W., Caspi, A., Corcoran, D. L., Sugden, K., Poulton, R., Arseneault, L., Baccarelli, A., Chamarti, K., Gao, X., Hannon, E., Harrington, H. L., Houts, R., Kothari, M., Kwon, D., Mill, J., Schwartz, J., Vokonas, P., Wang, C., Williams, B. S., & Moffitt, T. E. (2022). DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife, 11, Artikel e73420. Biomarkers of Aging Consortium, Herzog, C. M. S., Goeminne, L. J. E., Poganik, J. R., Barzilai, N., Belsky, D. W., Betts-LaCroix, J., Chen, B. H., Chen, M., Cohen, A. A., Cummings, S. R., Fedichev, P. O., Ferrucci, L., Fleming, A., Fortney, K., Furman, D., Gorbunova, V., Higgins-Chen, A., Hood, L., . . . Gladyshev, V. N. (2024). Challenges and recommendations for the translation of biomarkers of aging. Nature Aging, 4(10), 1372–1383. Bischoff-Ferrari, H. A., Gängler, S., Wieczorek, M., Belsky, D. W., Ryan, J., Kressig, R. W., Stähelin, H. B., Theiler, R., Dawson-Hughes, B., Rizzoli, R., Vellas, B., Rouch, L., Guyonnet, S., Egli, A., Orav, E. J., Willett, W., & Horvath, S. (2025). Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, 5(3), 376–385. Diego D. (2025, 3. Februar). BioAge – Why do inconsistencies/incorrect calculation occur? EGYM Help Center. Diego D. (2026, 6. Juli). What is BioAge? EGYM Help Center. Dwaraka, V. B., Aronica, L., Carreras-Gallo, N., Robinson, J. L., Hennings, T., Carter, M. M., Corley, M. J., Lin, A., Turner, L., Smith, R., Mendez, T. L., Went, H., Ebel, E. R., Sonnenburg, E. D., Sonnenburg, J. L., & Gardner, C. D. (2024). Unveiling the epigenetic impact of vegan vs. omnivorous diets on aging: Insights from the Twins Nutrition Study (TwiNS). BMC Medicine, 22, Artikel 301. EGYM. (o. D.-a). EGYM BioAge. EGYM. (o. D.-b). The EGYM BioAge motivates club members. EGYM. (o. D.-c). The evolution of EGYM BioAge. Garmin. (2025, 22. April). What is your Garmin fitness age? How can you lower it? Higgins-Chen, A. T., Thrush, K. L., Wang, Y., Minteer, C. J., Kuo, P.-L., Wang, M., Niimi, P., Sturm, G., Lin, J., Moore, A. Z., Bandinelli, S., Vinkers, C. H., Vermetten, E., Rutten, B. P. F., Geuze, E., Okhuijsen-Pfeifer, C., van der Horst, M. Z., Schreiter, S., Gutwinski, S., . . . Levine, M. E. (2022). A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. Nature Aging, 2(7), 644–661. Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biology, 14(10), Artikel R115. Ibáñez-Cabellos, J. S., García-Giménez, J. L., Escobar, J., Pallardó, F. V., & Mena-Mollá, S. (2026). From the lab to lifestyle: Epigenetic clocks in personalized aging and health. Biogerontology, 27, Artikel 101. Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Hou, L., Baccarelli, A. A., Stewart, J. D., Li, Y., Whitsel, E. A., Wilson, J. G., Reiner, A. P., Aviv, A., Lohman, K., Liu, Y., Ferrucci, L., & Horvath, S. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging, 10(4), 573–591. Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., Hou, L., Baccarelli, A. A., Li, Y., Stewart, J. D., Whitsel, E. A., Assimes, T. L., Ferrucci, L., & Horvath, S. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging, 11(2), 303–327. Mandsager, K., Harb, S., Cremer, P., Phelan, D., Nissen, S. E., & Jaber, W. (2018). Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open, 1(6), Artikel e183605. Moqri, M., Herzog, C., Poganik, J. R., Ying, K., Justice, J. N., Belsky, D. W., Higgins-Chen, A. T., Chen, B. H., Cohen, A. A., Fuellen, G., Hägg, S., Marioni, R. E., Widschwendter, M., Fortney, K., Fedichev, P. O., Zhavoronkov, A., Barzilai, N., Lasky-Su, J., Kiel, D. P., . . . Ferrucci, L. (2024). Validation of biomarkers of aging. Nature Medicine, 30(2), 360–372. Oura Team. (2025, 1. April). All about cardiovascular age. The Pulse Blog. TANITA. (o. D.-a). Bioelectrical impedance analysis. TANITA. (o. D.-b). Understanding your measurements. Waziry, R., Ryan, C. P., Corcoran, D. L., Huffman, K. M., Kobor, M. S., Kothari, M., Graf, G. H., Kraus, V. B., Kraus, W. E., Lin, D. T. S., Pieper, C. F., Ramaker, M. E., Bhapkar, M., Das, S. K., Ferrucci, L., Hastings, W. J., Kebbe, M., Parker, D. C., Racette, S. B., . . . Belsky, D. W. (2023). Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging, 3(3), 248–257. WHOOP. (2026, 21. April). Healthspan: WHOOP age & pace of aging guide. Ying, K., Paulson, S., Eames, A., Tyshkovskiy, A., Li, S., Eynon, N., Jacques, M., Grolaux, R., Seale, K., Jacques, E., Goeminne, L. J. E., Cipriano, A., Perez-Guevara, M., Emamifar, M., Casas Martínez, M., Kwon, D., Kosheleva, A., Snyder, M., Gobel, D., . . . Gladyshev, V. N. (2025). A unified framework for systematic curation and evaluation of aging biomarkers. Nature Aging, 5(11), 2323–2339.

Dominik hat sein EGYM-BioAge ermittelt – doch was sagt diese Zahl über seine Gesundheit aus? Wir erklären, was hinter dem biologischen Alter steckt und wie Studiogeräte, Wearables und epigenetische Tests zu ihren Ergebnissen kommen. Wie zuverlässig sind diese Werte? Können Training und Ernährung unsere biologische Uhr beeinflussen? Und wann motiviert ein Alterswert zu gesunden Gewohnheiten, wann führt er in die Irre? ------------------------------------------------------------------------ Dominiks Buch zur pflanzenbasierten Sporternährung im UTB-Verlag: https://www.utb.de/doi/book/10.36198/9783838560328 Dominiks Gesundheitscommunity: www.gsundes-hannover.de Dominiks Online-Knie-Kurs: https://gsundes-hannover.de/knieschmerzen/ Dominiks Online-Rücken-Kurs: https://copecart.com/products/34bd5abb/checkout Marcs veganes Online-Fitness-Coaching: https://vegainer-academy.com/ Marcs Online-Kurs: https://www.copecart.com/products/a50f88f2/checkout ------------------------------------------------------------------------ Werbung: Dieser Podcast wird unterstützt von der Firma Watson Nutrition. Die Firma bietet als einzige umfassend laborgeprüfte Nahrungsergänzungsmittel für eine optimierte Nährstoffversorgung. Zum Angebot zählen Multi-Supplemente, Mono-Supplemente, Sportsupplemente wie Kreatin oder auch Proteinriegel, Shakes und essenzielle Aminosäuren Mit dem Code veganperformance erhältst du 5 % Rabatt auf deine Bestellung.  Zur Firmenwebseite: Watson Nutrition ------------------------------------------------------------------------ Kapitelmarken: 00:00:00 Intro: Biologisches Alter auf dem Prüfstand 00:00:52 Dominiks BioAge: Von 39 auf 24 Jahre 00:05:44 Fitness früher und heute: Leistung, Alltag und Wohlbefinden 00:11:48 Was bedeutet biologisches Alter überhaupt? 00:15:46 Körperliche Tests: Kraft, Beweglichkeit und Stoffwechsel 00:18:55 Blutwerte, Telomere und epigenetische Tests 00:22:41 Smartwatches, Ringe und Waagen: Welche Werte liefern sie? 00:27:55 EGYM BioAge: Wie entsteht die Alterszahl? 00:31:51 Neue Algorithmen: Wie vergleichbar bleiben die Ergebnisse? 00:33:09 Werbung: Watson Nutrition 00:34:18 Biologisches Alter senken: Was zeigen die Studien? 00:42:18 Vegane Ernährung und Altern: Die Zwillingsstudie 00:48:53 Vorteile: Motivation und sichtbare Fortschritte 00:53:08 Nachteile: Stress und Selbstoptimierungsdruck 01:00:22 Messgenauigkeit, Scheinsicherheit und Marketing 01:06:07 Fazit: Was für ein gesundes Leben wirklich zählt ------------------------------------------------------------------------ Quellen: Belsky, D. W., Caspi, A., Corcoran, D. L., Sugden, K., Poulton, R., Arseneault, L., Baccarelli, A., Chamarti, K., Gao, X., Hannon, E., Harrington, H. L., Houts, R., Kothari, M., Kwon, D., Mill, J., Schwartz, J., Vokonas, P., Wang, C., Williams, B. S., & Moffitt, T. E. (2022). DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife, 11, Artikel e73420. Biomarkers of Aging Consortium, Herzog, C. M. S., Goeminne, L. J. E., Poganik, J. R., Barzilai, N., Belsky, D. W., Betts-LaCroix, J., Chen, B. H., Chen, M., Cohen, A. A., Cummings, S. R., Fedichev, P. O., Ferrucci, L., Fleming, A., Fortney, K., Furman, D., Gorbunova, V., Higgins-Chen, A., Hood, L., . . . Gladyshev, V. N. (2024). Challenges and recommendations for the translation of biomarkers of aging. Nature Aging, 4(10), 1372–1383. Bischoff-Ferrari, H. A., Gängler, S., Wieczorek, M., Belsky, D. W., Ryan, J., Kressig, R. W., Stähelin, H. B., Theiler, R., Dawson-Hughes, B., Rizzoli, R., Vellas, B., Rouch, L., Guyonnet, S., Egli, A., Orav, E. J., Willett, W., & Horvath, S. (2025). Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial. Nature Aging, 5(3), 376–385. Diego D. (2025, 3. Februar). BioAge – Why do inconsistencies/incorrect calculation occur? EGYM Help Center. Diego D. (2026, 6. Juli). What is BioAge? EGYM Help Center. Dwaraka, V. B., Aronica, L., Carreras-Gallo, N., Robinson, J. L., Hennings, T., Carter, M. M., Corley, M. J., Lin, A., Turner, L., Smith, R., Mendez, T. L., Went, H., Ebel, E. R., Sonnenburg, E. D., Sonnenburg, J. L., & Gardner, C. D. (2024). Unveiling the epigenetic impact of vegan vs. omnivorous diets on aging: Insights from the Twins Nutrition Study (TwiNS). BMC Medicine, 22, Artikel 301. EGYM. (o. D.-a). EGYM BioAge. EGYM. (o. D.-b). The EGYM BioAge motivates club members. EGYM. (o. D.-c). The evolution of EGYM BioAge. Garmin. (2025, 22. April). What is your Garmin fitness age? How can you lower it? Higgins-Chen, A. T., Thrush, K. L., Wang, Y., Minteer, C. J., Kuo, P.-L., Wang, M., Niimi, P., Sturm, G., Lin, J., Moore, A. Z., Bandinelli, S., Vinkers, C. H., Vermetten, E., Rutten, B. P. F., Geuze, E., Okhuijsen-Pfeifer, C., van der Horst, M. Z., Schreiter, S., Gutwinski, S., . . . Levine, M. E. (2022). A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking. Nature Aging, 2(7), 644–661. Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biology, 14(10), Artikel R115. Ibáñez-Cabellos, J. S., García-Giménez, J. L., Escobar, J., Pallardó, F. V., & Mena-Mollá, S. (2026). From the lab to lifestyle: Epigenetic clocks in personalized aging and health. Biogerontology, 27, Artikel 101. Levine, M. E., Lu, A. T., Quach, A., Chen, B. H., Assimes, T. L., Bandinelli, S., Hou, L., Baccarelli, A. A., Stewart, J. D., Li, Y., Whitsel, E. A., Wilson, J. G., Reiner, A. P., Aviv, A., Lohman, K., Liu, Y., Ferrucci, L., & Horvath, S. (2018). An epigenetic biomarker of aging for lifespan and healthspan. Aging, 10(4), 573–591. Lu, A. T., Quach, A., Wilson, J. G., Reiner, A. P., Aviv, A., Raj, K., Hou, L., Baccarelli, A. A., Li, Y., Stewart, J. D., Whitsel, E. A., Assimes, T. L., Ferrucci, L., & Horvath, S. (2019). DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging, 11(2), 303–327. Mandsager, K., Harb, S., Cremer, P., Phelan, D., Nissen, S. E., & Jaber, W. (2018). Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open, 1(6), Artikel e183605. Moqri, M., Herzog, C., Poganik, J. R., Ying, K., Justice, J. N., Belsky, D. W., Higgins-Chen, A. T., Chen, B. H., Cohen, A. A., Fuellen, G., Hägg, S., Marioni, R. E., Widschwendter, M., Fortney, K., Fedichev, P. O., Zhavoronkov, A., Barzilai, N., Lasky-Su, J., Kiel, D. P., . . . Ferrucci, L. (2024). Validation of biomarkers of aging. Nature Medicine, 30(2), 360–372. Oura Team. (2025, 1. April). All about cardiovascular age. The Pulse Blog. TANITA. (o. D.-a). Bioelectrical impedance analysis. TANITA. (o. D.-b). Understanding your measurements. Waziry, R., Ryan, C. P., Corcoran, D. L., Huffman, K. M., Kobor, M. S., Kothari, M., Graf, G. H., Kraus, V. B., Kraus, W. E., Lin, D. T. S., Pieper, C. F., Ramaker, M. E., Bhapkar, M., Das, S. K., Ferrucci, L., Hastings, W. J., Kebbe, M., Parker, D. C., Racette, S. B., . . . Belsky, D. W. (2023). Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging, 3(3), 248–257. WHOOP. (2026, 21. April). Healthspan: WHOOP age & pace of aging guide. Ying, K., Paulson, S., Eames, A., Tyshkovskiy, A., Li, S., Eynon, N., Jacques, M., Grolaux, R., Seale, K., Jacques, E., Goeminne, L. J. E., Cipriano, A., Perez-Guevara, M., Emamifar, M., Casas Martínez, M., Kwon, D., Kosheleva, A., Snyder, M., Gobel, D., . . . Gladyshev, V. N. (2025). A unified framework for systematic curation and evaluation of aging biomarkers. Nature Aging, 5(11), 2323–2339.

What if the one signal you can't fake is already in your pocket? Your voice changes when you are stressed, tired, or run down, and Alex Fredericks built a company that reads it. ToneWell founder Alex Fredericks explains how a 30-second voice clip is analyzed against a static database to extrapolate about 1,000 biomarkers, delivered as a prioritized wellness report in minutes. No blood, no wearable. Meet our guest Alexander B. Fredericks is a growth engineer and the founder of ToneWell and AECC Group. After more than twenty years in brand, media, and the music business, he turned the voice into a wellness analytic, built on a 30-second Performance Readiness Scan and validated by his co-founder Dr. Bear Walker, a double-PhD pioneer of bio-tracking machines. Thank you to our partners Outliyr Biohacker's Peak Performance Shop: get exclusive discounts on cutting-edge health, wellness, & performance gear Ultimate Health Optimization Deals: a database of of all the current best biohacking deals on technology, supplements, systems and more Latest Summits, Conferences, Masterclasses, and Health Optimization Events: join me at the top events around the world FREE Outliyr Nootropics Mini-Course: gain mental clarity, energy, motivation, and focus Key takeaways A 30-second voice clip can extrapolate around 1,000 biomarkers, with a report in under five minutes. Voice is topical: readable in the moment, unlike a blood panel that takes an appointment, a draw, a lab, and a callback. Your baseline is stable, but your in-the-moment values shift, so a single lab draw can miss both. A hard training day burns through magnesium, potassium, zinc, boron, and copper. A wearable gives you a sleep score but not the reason, like a low magnesium form. The science of frequency is old; what is new is the delivery speed. Alex uses ToneWell mostly as his own recovery tool. Episode highlights 1:38 What ToneWell reads in 30 seconds 2:50 How your voice becomes data 22:35 Baseline versus the moment 24:53 Minerals that stress burns 40:10 Nick's own scan 53:31 Meet the BioTracker 58:13 Wellbeing over wellness Links Watch it on YouTube: https://youtu.be/XjKp0wcbhmQ  Full episode show notes: https://outliyr.com/277 Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick

Matthew Lee, Jeffrey A SoRelle, Arun Everest-Dass, David E Gerber, Mitchell S von Itzstein. Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy. Clin Chem 2026; 72(9): 926–47. https://doi.org/10.1093/clinchem/hvag062

In recent years, the U.S. Food and Drug Administration (FDA) has approved new biomarker tools for Alzheimer's disease, including blood tests and tracers for brain scans. How are these tools used in research to help develop new Alzheimer's treatments? Dr. Henrik Zetterberg returns to the podcast to discuss how blood tests, brain scans and other biomarker developments are transforming clinical trials and treatments for Alzheimer's disease and other neurodegenerative conditions ahead of his upcoming Healthy Living with Mild Cognitive Impairment (MCI) event. Guest: Henrik Zetterberg, MD, PhD, professor of neurochemistry, University of Gothenburg, visiting professor, University of Wisconsin−Madison and University College London, Biomarker Core leader, Wisconsin Alzheimer's Disease Research Center Show Notes Register and learn more about the upcoming Healthy Living with MCI event featuring Dr. Zetterberg, happening on September 11, 2026, and future programs on our website. Register and learn more about the upcoming Fall Community Conversation, happening on September 29, 2026, on our website. Listen to our past episodes with Dr. Zetterberg, “Addressing Cochrane's Review on Amyloid-Targeting Treatments for Alzheimer's Disease” and “The Future of Fluid Biomarkers for Alzheimer's Disease and Related Dementias,” on our website. Learn more about LATE, mentioned by Dr. Zetterberg at 24:05, by listening to our episode “LATE, Explained” on our website. Read more about the Alzheimer's disease blood tests recently approved by the U.S. FDA on our website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook, Instagram and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production. Learn about Dr. Chin's book, When Memory Fades: What to Expect at Every Stage, from Early Signs to Full Support for Alzheimer's and Dementia.

In this podcast episode, BJ Rimel, MD, and Elizabeth Lee, MD, discuss the scientific rationale for targeting CDH6 in ovarian cancer and the emerging role of CDH6-directed antibody–drug conjugates (ADCs) in platinum-resistant disease, including:CDH6 biology, expression patterns, and its potential as a therapeutic target in ovarian cancerEarly-phase efficacy data with investigational CDH6-directed ADCs, including raludotatug deruxtecan (R-DXd) and CUSP06, and an ongoing phase III trial of R-DXdSafety considerations with CDH6-directed ADCs, including cytopenias, gastrointestinal toxicities, fatigue, and interstitial lung disease/pneumonitisConsiderations for sequencing ADCs, including the potential impact of target expression, payload class, and mechanisms of resistancePresenters:BJ Rimel, MDDivision Chief, Gynecologic OncologyProfessor, Department of OB/GYNUniversity of WashingtonClinical Director of Gynecologic OncologyFred Hutchinson Cancer CenterSeattle, WashingtonElizabeth Lee, MDDivision of Gynecologic OncologyCenter for Cancer Therapeutic InnovationDepartment of Medical OncologyDana-Farber Cancer InstituteBoston, MassachusettsLink to full program: https://bit.ly/3SqCAZ6Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Functional medicine promised to move healthcare beyond disease labels, symptom management, and one-size-fits-all treatment. But increasingly, it is recreating the very disease model it was meant to replace—masked by less-conventional diagnoses and arrays of supplements instead of prescriptions. In this opening episode of a new Beyond the Biomarkers series, Kerri Rachelle examines how root-cause care lost its way: prescription cascades becoming supplement cascades, test results becoming diagnoses they cannot establish, therapeutic nutrition becoming restriction, complexity being mistaken for personalization, and emerging science being presented with false certainty. She also explores why patients are still being left alone between appointments, why nutrition expertise must be central to any model built around food, and why Registered Dietitians should help lead the next chapter of functional medicine. This is not a rejection of functional medicine. It is an honest call to repair it. Follow Beyond the Biomarkers as each episode takes a deeper look at where functional medicine went wrong—and how we can build the thoughtful, evidence-based, whole-person model of care it was always supposed to become. Become a REV0lution patient Interested in insurance-covered functional medicine and personalized nutrition care? Request care and verify your coverage with REV0lution. Work privately with Kerri To inquire about Kerri's private functional medicine care, email kerri@kerrirachelle.com with Private Care in the subject line. This podcast is for educational purposes only and does not provide individual medical advice, diagnosis, or treatment.

Neurologist David Perlmutter MD says the beta-amyloid theory of Alzheimer's is wrong — and the real culprit is your brain's own immune cells. In this episode of Health Longevity Secrets, Robert Lufkin MD sits down with the #1 New York Times bestselling author to unpack his new book Brain Defenders: how diet, blood sugar, and metabolic health flip the brain's microglia from protective to destructive, why anti-amyloid drugs offer "trivial" benefit, and which biomarkers actually predict your brain's future.Chapters:00:00 — Introduction01:38 — Why He Left Mainstream Neurology to Prevent Brain Decline05:24 — Building the World's Largest Integrative Neurology Practice06:55 — The Common Pathway From Metabolism to Brain Degeneration08:25 — Why the Beta-Amyloid Theory of Alzheimer's Is Wrong09:11 — What Are Microglia? The Brain's Immune Cells (M1 vs M2)12:13 — From Brain "Glue" to Master Regulators of Your Synapses16:00 — How Body Inflammation and Cytokines Reach the Brain18:15 — Leaky Gut, the Microbiome, and Brain Degeneration19:46 — Ultra-Processed Foods Raise Alzheimer's Risk Up to 270%25:02 — Synaptic Pruning: The Link Between Autism, ADHD and Alzheimer's29:36 — Why Diabetics Recover Worse From Head Trauma31:51 — Anti-Amyloid Drugs: "Trivial" Benefit, Serious Harm35:37 — The Biomarkers to Track: Fasting Glucose, Insulin, A1C40:09 — On the Horizon: Mitochondrial Therapies and Microglial Transplants45:26 — Glyphosate, Air Pollution and 40Hz Light Therapy47:00 — Brain Defenders Releases August 18 — Final TakeawaysKey takeaways:Alzheimer's is increasingly understood as a "synaptopathy" — a disease of lost synapses driven by the brain's own immune cells (microglia), not simply beta-amyloid plaque.Microglia shift from supportive (M2) to destructive (M1) in response to metabolic signals: high blood sugar, insulin resistance, elevated blood pressure, excess body fat, and inflammation.A long-term cohort found each daily serving of ultra-processed food raised Alzheimer's risk ~13%, with 10+ servings/day linked to a 2.7-fold (270%) increase.A Cochrane review of anti-amyloid antibodies found "trivial" cognitive benefit alongside meaningful harm, including brain swelling and microbleeds (ARIA).The most actionable brain biomarkers are cheap and accessible: fasting glucose, fasting insulin, A1c, waist circumference, and a continuous glucose monitor — aim for optimal, not just "normal."Emerging frontiers target the mitochondria inside microglia — metformin, CoQ10, urolithin A, exercise, fasting, ketones, and 40Hz gamma light therapy.Studies & sources:Weinstein et al., J Prev Alzheimers Dis — ultra-processed food and Alzheimer's riskCochrane Review (2026) — anti-amyloid monoclonal antibodies for Alzheimer'sIaccarino, Tsai et al. (Tsai Lab, MIT) — 40Hz gamma light and microgliaDr. Lufkin's book "Lies I Taught in Medical School": https://robertlufkinmd.com/lies/⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every other Tuesday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

Drs. Montesi and Martinez discuss how the emerging PRIME-PPF clinical cohort study and biomarker research will sharpen definitions of disease progression and transform treatment decisions in non-IPF ILD. They highlight the potential for clinicians to use integrated data (eg, symptoms, physiology, imaging, and circulating proteomic signatures) to initiate antifibrotic and combination therapies earlier, tailoring them to individual patients while also balancing side effects and standard immunomodulatory care.

What if some of the most disabling symptoms in EDS, HSD, POTS, MCAS, ME/CFS, and long COVID are being driven by something we still struggle to see on standard testing? In this episode of Bendy Bodies, Dr. Linda Bluestein is joined by guest co-host Dr. Ina Stephens, Associate Director of the UVA Health EDS and Hypermobility Disorder Center, along with Brain Inflammation Collaborative co-founder Christy Jagdfeld and neuroscientist Dr. Megan Fitzgerald. Together, they explore the rapidly evolving science of brain inflammation, including what it actually means, how it differs from conditions like encephalitis or brain edema, and why it may matter in complex multisystem illness. The conversation dives into microglial activation, mast cell involvement in the central nervous system, and the challenge of detecting subtle neuroinflammation in living patients. The guests also discuss emerging research tools, including ultra-high-field MRI, PET ligands, and blood-based extracellular vesicles, that may eventually give clinicians a clearer window into what is happening inside the brain. The group also takes a closer look at the Brain Inflammation Collaborative's Unhide platform, which is collecting real-world, patient-reported data across more than 30 overlapping chronic conditions, including EDS, POTS, MCAS, ME/CFS, and long COVID. Early findings raise important questions about quality of life, symptom burden, the limitations of the Beighton score, and why pediatric research may be especially important. The episode closes with practical implications, including why pacing matters when exercise can worsen symptoms rather than improve them, and what patients and clinicians should watch as this field moves forward. Takeaways “Brain inflammation” can involve subtle processes such as microglial activation and mast cell signaling that may not appear on routine MRI or CT scans. Emerging tools such as ultra-high-field MRI, PET imaging, and blood-based extracellular vesicles may eventually help researchers detect and track neuroinflammation in living patients. The Unhide platform has collected real-world data from thousands of participants with overlapping chronic conditions, offering a new way to study symptom burden and quality of life outside traditional clinical trials. The Beighton score may not reflect functional severity or symptom burden, highlighting the need for better ways to assess hypermobility over time. Pediatric research is urgently needed to understand how these conditions develop and whether earlier recognition could change long-term outcomes. Want more of the Brain Inflammation Collaborative? https://www.unhidenow.org/ https://www.braininflammation.org/ Want to learn more about the UVA EDS Center? For Appointments and Questions: RUVAEDSCenter@uvahealth.org UVA EDS: https://www.uvahealth.com/healthy-practice/advancing-care-through-ehlers-danlos-clinic UVA EDS FAQ: https://www.uvahealth.com/support/eds/faq UVA Pediatric Integrative Medicine: https://childrens.uvahealth.com/specialties/integrative-health Want more Dr. Linda Bluestein, MD? Website: https://www.hypermobilitymd.com/ YouTube: https://www.youtube.com/@bendybodiespodcast Instagram: ⁠⁠⁠⁠https://www.instagram.com/hypermobilitymd/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://www.facebook.com/BendyBodiesPodcast⁠⁠⁠⁠ X: ⁠⁠⁠⁠https://twitter.com/BluesteinLinda⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/in/hypermobilitymd/⁠⁠⁠⁠ Newsletter: ⁠⁠⁠⁠https://hypermobilitymd.substack.com/ Shop my Amazon store ⁠⁠⁠ https://www.amazon.com/shop/hypermobilitymd Dr. Bluestein's Recommended Herbs, Supplements and Care Necessities: https://us.fullscript.com/welcome/hypermobilitymd/store-start Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at ⁠⁠https://www.bendybodiespodcast.com/⁠⁠. YOUR bendy body is our highest priority!⁠⁠ Learn more about Human Content at ⁠⁠⁠http://www.human-content.com⁠⁠⁠ Podcast Advertising/Business Inquiries: ⁠⁠⁠sales@human-content.com⁠⁠⁠ Part of the Human Content Podcast Network Go to AirDoctorPro.com and use promo code BENDY_ to get UP TO $300 off today! FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links Chapters: 00:00 Beighton Score Debate00:28 Meet the Guests02:54 Why BIC Was Founded07:22 Defining Brain Inflammation09:44 Biomarkers and Imaging Advances18:12 Unhide Platform and Real World Data25:55 Comorbidities and Survey Cadence31:40 Survey Fatigue Solutions32:49 Tools Beyond Beighton34:16 Research Priorities Wish List35:41 Biomarkers EVs Immune Profiling38:37 Pediatric Focus Early Signs46:34 Building Pediatric Platform53:07 Hacks Resources And Wrap Up Learn more about your ad choices. Visit megaphone.fm/adchoices

What if some of the most disabling symptoms in EDS, HSD, POTS, MCAS, ME/CFS, and long COVID are being driven by something we still struggle to see on standard testing? In this episode of Bendy Bodies, Dr. Linda Bluestein is joined by guest co-host Dr. Ina Stephens, Associate Director of the UVA Health EDS and Hypermobility Disorder Center, along with Brain Inflammation Collaborative co-founder Christy Jagdfeld and neuroscientist Dr. Megan Fitzgerald. Together, they explore the rapidly evolving science of brain inflammation, including what it actually means, how it differs from conditions like encephalitis or brain edema, and why it may matter in complex multisystem illness. The conversation dives into microglial activation, mast cell involvement in the central nervous system, and the challenge of detecting subtle neuroinflammation in living patients. The guests also discuss emerging research tools, including ultra-high-field MRI, PET ligands, and blood-based extracellular vesicles, that may eventually give clinicians a clearer window into what is happening inside the brain. The group also takes a closer look at the Brain Inflammation Collaborative's Unhide platform, which is collecting real-world, patient-reported data across more than 30 overlapping chronic conditions, including EDS, POTS, MCAS, ME/CFS, and long COVID. Early findings raise important questions about quality of life, symptom burden, the limitations of the Beighton score, and why pediatric research may be especially important. The episode closes with practical implications, including why pacing matters when exercise can worsen symptoms rather than improve them, and what patients and clinicians should watch as this field moves forward. Note: Technical difficulties knocked Dr. Linda Bluestein offline halfway through the taping; thankfully, Dr. Ina Stephens carried the rest of conversation. Takeaways “Brain inflammation” can involve subtle processes such as microglial activation and mast cell signaling that may not appear on routine MRI or CT scans. Emerging tools such as ultra-high-field MRI, PET imaging, and blood-based extracellular vesicles may eventually help researchers detect and track neuroinflammation in living patients. The Unhide platform has collected real-world data from thousands of participants with overlapping chronic conditions, offering a new way to study symptom burden and quality of life outside traditional clinical trials. The Beighton score may not reflect functional severity or symptom burden, highlighting the need for better ways to assess hypermobility over time. Want more of the Brain Inflammation Collaborative? https://www.unhidenow.org/ https://www.braininflammation.org/ Want to learn more about the UVA EDS Center? For Appointments and Questions: RUVAEDSCenter@uvahealth.org UVA EDS: https://www.uvahealth.com/healthy-practice/advancing-care-through-ehlers-danlos-clinic UVA EDS FAQ: https://www.uvahealth.com/support/eds/faq UVA Pediatric Integrative Medicine: https://childrens.uvahealth.com/specialties/integrative-health Want more Dr. Linda Bluestein, MD? Website: https://www.hypermobilitymd.com/ YouTube: https://www.youtube.com/@bendybodiespodcast Instagram: ⁠⁠⁠⁠https://www.instagram.com/hypermobilitymd/⁠⁠⁠⁠ Facebook: ⁠⁠⁠⁠https://www.facebook.com/BendyBodiesPodcast⁠⁠⁠⁠ X: ⁠⁠⁠⁠https://twitter.com/BluesteinLinda⁠⁠⁠⁠ LinkedIn: ⁠⁠⁠⁠https://www.linkedin.com/in/hypermobilitymd/⁠⁠⁠⁠ Newsletter: ⁠⁠⁠⁠https://hypermobilitymd.substack.com/ Shop my Amazon store ⁠⁠⁠ https://www.amazon.com/shop/hypermobilitymd Dr. Bluestein's Recommended Herbs, Supplements and Care Necessities: https://us.fullscript.com/welcome/hypermobilitymd/store-start Thank YOU so much for tuning in. We hope you found this episode informative, inspiring, useful, validating, and enjoyable. Join us on the next episode for YOUR time to level up your knowledge about hypermobility disorders and the people who have them. Join YOUR Bendy Bodies community at ⁠⁠https://www.bendybodiespodcast.com/⁠⁠. YOUR bendy body is our highest priority!⁠⁠ Learn more about Human Content at ⁠⁠⁠http://www.human-content.com⁠⁠⁠ Podcast Advertising/Business Inquiries: ⁠⁠⁠sales@human-content.com⁠⁠⁠ Part of the Human Content Podcast Network Go to AirDoctorPro.com and use promo code BENDY_ to get UP TO $300 off today! FTC: This video is not sponsored. Links are commissionable, meaning I may earn commission from purchases made through links Chapters: 00:00 Beighton Score Debate00:28 Meet the Guests02:54 Why BIC Was Founded07:22 Defining Brain Inflammation09:44 Biomarkers and Imaging Advances18:12 Unhide Platform and Real World Data25:55 Comorbidities and Survey Cadence31:40 Survey Fatigue Solutions32:49 Tools Beyond Beighton34:16 Research Priorities Wish List35:41 Biomarkers EVs Immune Profiling38:37 Pediatric Focus Early Signs46:34 Building Pediatric Platform53:07 Hacks Resources And Wrap Up Learn more about your ad choices. Visit megaphone.fm/adchoices

The latest episode of QuidelOrtho Science Bytes takes listeners inside the 2026 ADLM Annual Conference, where experts discussed emerging technologies and diagnostic innovations shaping the future of healthcare.   Host Stephanie Kleewein speaks with three industry experts about advances in ultra-fast PCR, procalcitonin-guided antibiotic stewardship and high-sensitivity troponin testing. Together, they explore how faster, more precise diagnostics are helping clinicians make better decisions for patients.   About Our Speakers:  Dr. Heather Danks, Chief Technology Officer at LEX Diagnostics Dr. Mike Broyles, Director of Medical Affairs for Biomarkers at Thermo Fisher Scientific Dr. Lindy Carlstrom, Medical Affairs Manager at QuidelOrtho

Professor Maria Fleseriu and Professor Mark Gurnell focus on predictors of response to medical therapy, including the role of imaging characteristics, pathological and molecular markers, and biochemical parameters in guiding treatment decisions to support individualized patient care.   This educational podcast series is intended for US healthcare professionals only. It was developed by expert faculty in collaboration with The Pituitary Society and Amiculum, with support from Recordati Rare Diseases through an independent educational grant. Recordati Rare Diseases had no involvement in content development, speaker selection, or editorial decisions. Discussions in this series are informed by the 2025 consensus on therapeutic outcomes in acromegaly (Melmed S et al. Nat Rev Endocrinol 2025;21:718–37). Speaker disclosures: Maria Fleseriu (Oregon Health and Science University, Portland, USA). Research grants to her university from Crinetics Pharmaceuticals and Debio. Scientific consulting fees from Crinetics Pharmaceuticals, Camurus AB, Marea and Recordati Rare Diseases. Mark Gurnell (University of Cambridge School of Clinical Medicine, Cambridge, England) - Consulting honoraria and speaker fees from Camurus AB, Marea Therapeutics and Recordati Rare Diseases.  

Dr. Manish Arora, CEO at LinusBio, has developed an innovative approach to precision medicine through the Traced test, which measures exposure to trace elements and environmental toxins using hair biomarkers. The technology analyzes a small hair sample and can measure chemicals that enter the bloodstream and deposit in the hair as it grows.  This exposome-based test identifies exposure patterns through longitudinal monitoring and provides a precise method to measure environmental impacts, unlike genomic biomarkers, and offers actionable guidance for reducing toxic exposure. Manish explains, "So we like using hair for many reasons. One is we can collect it very easily at home. All you need is a pair of household scissors, a quick snip, and we only ask you for about three to five strands. We don't need a whole lot. What is amazing about hair is that it can actually give you a daily readout over the past month. And let me share with you how this happens. If you've ever seen a tree that's been cut down and you've seen growth rings in it, we think of them as yearly  growth rings."   "And here there's a growth ring forming almost every hour. So in fact, if you were able to take a strand of hair one centimeter, you would get a whole month of readout at an hourly resolution. That's like 800 to a thousand sequential blood tests. And that's what we have figured out. So unlike many other tests that just give you one number, we give you your monthly profile. Again, all from just one centimeter of hair." "The Traced test, as its first offering, is looking at essential elements like zinc and copper, but also the toxic metals that so many of us have heard of and are concerned about, like lead, cadmium, and arsenic. So what it does is it measures 15 different trace elements, the good and the bad, gives you an overall score, but gives you a daily profile over the last month. And there are such interesting patterns that we find. We find people who have high exposures every five to six days. And very often, when we speak to them, they're doing something very different on the weekend, which is a source of exposure. So we keep finding these patterns and instead of just saying, "Hey, you are high or low," we can work with them, look at these patterns, and then give them exposure guidance. Simple steps: how to improve your environment, how to reduce your toxic exposures." #LinusBio #TracedTest #PrecisionMedicine #Exposome #DigitalBiomarkers #EnvironmentalHealth #PreventiveCare #HealthcareInnovation #Diagnostics #Toxins #Wellness #HealthTech #Environment  linusbio.com Download the transcript here

Dr. Manish Arora, CEO at LinusBio, has developed an innovative approach to precision medicine through the Traced test, which measures exposure to trace elements and environmental toxins using hair biomarkers. The technology analyzes a small hair sample and can measure chemicals that enter the bloodstream and deposit in the hair as it grows.  This exposome-based test identifies exposure patterns through longitudinal monitoring and provides a precise method to measure environmental impacts, unlike genomic biomarkers, and offers actionable guidance for reducing toxic exposure. Manish explains, "So we like using hair for many reasons. One is we can collect it very easily at home. All you need is a pair of household scissors, a quick snip, and we only ask you for about three to five strands. We don't need a whole lot. What is amazing about hair is that it can actually give you a daily readout over the past month. And let me share with you how this happens. If you've ever seen a tree that's been cut down and you've seen growth rings in it, we think of them as yearly  growth rings."   "And here there's a growth ring forming almost every hour. So in fact, if you were able to take a strand of hair one centimeter, you would get a whole month of readout at an hourly resolution. That's like 800 to a thousand sequential blood tests. And that's what we have figured out. So unlike many other tests that just give you one number, we give you your monthly profile. Again, all from just one centimeter of hair." "The Traced test, as its first offering, is looking at essential elements like zinc and copper, but also the toxic metals that so many of us have heard of and are concerned about, like lead, cadmium, and arsenic. So what it does is it measures 15 different trace elements, the good and the bad, gives you an overall score, but gives you a daily profile over the last month. And there are such interesting patterns that we find. We find people who have high exposures every five to six days. And very often, when we speak to them, they're doing something very different on the weekend, which is a source of exposure. So we keep finding these patterns and instead of just saying, "Hey, you are high or low," we can work with them, look at these patterns, and then give them exposure guidance. Simple steps: how to improve your environment, how to reduce your toxic exposures." #LinusBio #TracedTest #PrecisionMedicine #Exposome #DigitalBiomarkers #EnvironmentalHealth #PreventiveCare #HealthcareInnovation #Diagnostics #Toxins #Wellness #HealthTech #Environment  linusbio.com  Listen to the podcast here

When is cerebrospinal fluid (CSF) biomarker testing the best choice for diagnosing Alzheimer's disease (AD)? Credit available for this activity expires: 8/19/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/alzheimers-disease-precision-diagnostics-3-part-live-2026a1000rmh?ecd=bdc_podcast_libsyn_mscpedu

I talk with clinical psychologist Dr Jake Hollis about recovering from ME/CFS and Long Covid, and why the nervous system offers a more useful frame than the tired “mind versus body” argument. We explore how validation, language, and recovery stories can shift the brain's predictions and open up real possibilities for change. • Jake's lived experience of long-term illness and a slow recovery path • How neuroplastic recovery therapies fit alongside biology rather than replacing it • Why recovery stories can create a visceral nervous system shift • The harm caused when recovered people are disbelieved or silenced • How the mind body divide shows up in healthcare systems and culture • Biomarkers, legitimacy, and why absence of a test is not absence of illness • Mental health stigma as a hidden driver of conflict and miscommunication • Emotional suppression, shame, and “keep calm and carry on” conditioning • Blame versus responsibility as a more compassionate recovery framework Links:More about Jake: www.fatiguepsychologist.comUnlearn Your Pain in the US and in the UKHoward Schubiner chats to Rangan Chatterjee Message me! (I can't reply to these messages) For more information about Long Covid Breathing courses & workshops, please check out LongCovidBreathing.com (music credit - Brock Hewitt, Rule of Life) Support the show~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~Thankyou for joining me in The Recovery Room. If you found this episode useful & are able to, you can support the show by buying me a coffee or checking out the merchVisit The Recovery Room website: www.JackiesRecoveryRoom.com Follow me on social media channels: @JackiesRecoveryRoom **Disclaimer - you should not rely on any medical information contained in this Podcast and related materials in making medical, health-related or other decisions. Please consult a doctor or other health professional**

I'm so excited to bring this conversation to Inspire + Move! In part one of this two-part conversation., I'm joined by Dr. Arshad of LiifeHack Longevity to talk about what it can look like to take a more proactive, personalized approach to our health. After Matt and I went through the LiifeHack experience ourselves, I knew I wanted to dive deeper into the data, testing and insights that can help us better understand what is happening inside our bodies.We talk about the difference between simply living longer and actually extending the number of years we feel strong, capable and healthy. From preventative testing and biomarkers to body composition, recovery and knowing when more isn't always better, this conversation is such an interesting look at what it means to truly “age with agency.”Tune in to hear more about:• Creating LiifeHack Longevity and the gaps between traditional reactive healthcare and a more preventative approach.• The difference between lifespan and health span, and what it means to “age with agency.”• Valuable health markers and testing that can help give us a more complete picture of what is happening in our bodies.• Why body composition, including muscle mass, bone density and visceral fat, can tell us so much more than simply focusing on the number on the scale.• The importance of recovery for high achievers, and why constantly doing more with our training isn't always the answer.One of my biggest takeaways from this conversation is that knowledge gives us the opportunity to make more intentional choices. It's about understanding our own bodies, creating strong foundations and making small, meaningful changes that support how we want to feel now and for years to come.This is only part one of my conversation with Dr. Arshad, so stay tuned for part two as we continue diving into longevity, health optimization and what it can look like to take greater ownership of our health!Dr. Hack's LinksInstagram: @liifehacklongevityWebsite: https://liifehack.com/LiifeHack's Link Tree Location: 3170 Harvester Rd Unit 100, BurlingtonPhone: 905-333-3373Let's Connect!• INSPIRE + MOVE EVENTS• Instagram• Private Coaching• BENCHMARK FITNESS• Website• Facebook• TikTok

Drs. Griffiths and Chase explain type 2–high asthma as a multisystem inflammatory disease that often coexists with conditions like allergic rhinitis, sinus disease with polyps, eczema, food allergies, and eosinophilic esophagitis. They emphasize the importance of recognizing type 2–high patterns through history and biomarkers; they also discuss the roles of multidisciplinary care, optimized inhaler use, reduced steroid exposure, and targeted biologic therapy when asthma remains uncontrolled.

In this Huberman Lab Essentials episode, my guest is Dr. Sara Gottfried, M.D., a Harvard-trained, board-certified gynecologist and expert in female hormone health. We discuss the key biomarkers women should track at each stage of life and how cortisol, thyroid hormone, estrogen, progesterone, and testosterone shape energy, mood, metabolism, and long-term disease risk. We also discuss PCOS, the risks and benefits of oral contraceptives, and the shift in brain metabolism that begins in perimenopause. Dr. Gottfried explains actionable tools for hormone and micronutrient testing, nutrition, stress management, and cardiometabolic screening that women can use at any age. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman LMNT: https://drinklmnt.com/huberman Eight Sleep: https://eightsleep.com/huberman Timestamps (00:00:00) Female Hormone Health (00:00:24) Family History, Intergenerational Trauma; Endometriosis, Fibroids, PCOS (00:01:31) Biomarkers by Decade; Teens & Cortisol; 20s & Sex Hormones (00:03:35) Tool: Hormone Test Timing; Micronutrient Testing, Magnesium (00:05:41) Sponsor: LMNT (00:07:17) Tool: Smoothies, Greens Powders & Microbiome (00:08:12) Nutrient Panels, Antioxidants, B Vitamins, Glutathione (00:09:34) Constipation, Thyroid Dysfunction; Trauma & Female Physiology (00:11:50) Tools: Reduce Perceived Stress, Meditation, Yoga, Breathwork (00:13:30) Opportunities by Decade; Androgens & Testosterone Decline (00:14:50) PCOS, Diagnostic Criteria, Hirsutism, Cardiometabolic Risk (00:17:10) Insulin & Glucose; Tool: Continuous Glucose Monitors (00:18:05) Democratizing Health Data (00:18:52) Sponsor: AG1 (00:20:07) Longevity "Don'ts"; Chronic Cardio & Cortisol; Tool: Adaptive Exercise (00:22:46) Oral Contraceptives, Benefits & Ovarian Cancer Risk (00:24:27) Ovarian Cancer Symptoms, Bloating, CA-125 (00:25:51) Oral Contraceptive Risks, Progestins, Inflammation; SHBG & Testosterone (00:29:08) Clitoral Shrinkage; Tools: Alternatives for Painful Periods (00:30:14) Sponsor: Eight Sleep (00:31:32) Menopause & Perimenopause; 30s Hormonal Baseline (00:33:07) Female Brain, Cerebral Hypometabolism & Alzheimer's Risk (00:35:02) Slow Brain Energy, Hormone Therapy; Hot Flashes as Biomarkers (00:36:54) Tool: Coronary Artery Calcium Score Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

How can we best manage intermediate-risk bladder cancer to balance disease control, quality of life, and the growing range of treatment options? On this episode of the BackTable Urology Podcast, Dr. Ruchika Talwar interviews Dr. Charles “Chaz” Peyton about the challenges of treating recurrent low-grade, intermediate-risk non–muscle invasive bladder cancer. They highlight the high recurrence but low progression risk, the often-underappreciated impact of repeated TURBTs on patient well-being, and the evolving landscape of office-based and chemoablative therapies. --- Get the BackTable app https://www.backtable.com/app --- Timestamps 00:00 - Introduction05:58 - Comparing Office Ablation and OR TURBT08:26 - TURBT Impact on Quality of Life11:37 - Uncovering Hidden Patient Burdens and Costs14:44 - Integrating Chemoablation into Practice18:20 - ENVISION QoL Study Setup22:04 - Comparing TURBT Preferences27:40 - Counseling Risk-Averse Patients29:10 - Community Adoption Advice31:59 - Upcoming Clinical Trials35:28 - Biomarkers and Expanding Access36:23 - Final Thoughts and Closing Remarks --- More about this episode The conversation covers practical strategies like office-based surveillance and fulguration for small recurrences, identifying triggers for returning to the OR, and recognizing the hidden burdens of TURBT complications such as hematuria, incontinence, and unplanned ER visits. Dr. Peyton reviews the role of chemoablative options for selected patients, discusses trial data on patient-reported outcomes, and addresses the mixed evidence, high costs, and need for individualized decision-making. The episode also explores new intravesical and FGFR-targeted therapies, underscores the importance of cost-conscious adoption and biomarkers, and considers how management approaches must evolve, especially in community practice settings. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Send us Fan MailA 27 year old woman went to a longevity clinic in the Bronx for an NAD IV drip. Minutes later she was in cardiac arrest. She died a few hours after that. The person who ran the clinic held a medical license from the Dominican Republic, not the United States.Dr. Kevin White talks with Dr. Matt Kaeberlein, a researcher who studies why and how we age, about what that story actually tells us. His answer isn't really about NAD. It's about certainty. Kaeberlein has never seen evidence that NAD infusions help anyone, and the field's founding claim, that NAD declines with age and needs replacing, is now being questioned by the same scientists who study it. Clinics keep selling it with total confidence anyway.That same pattern shows up everywhere they go in this conversation. Kaeberlein now chairs Montana's expanded Right To Try review board, which lets biotech companies test experimental therapies on real patients once they clear a phase one safety bar, outside the usual FDA process. He explains why that could produce safety data the field has never had, and why he'd reject any therapy pitched without a real scientific rationale behind it, no matter how confidently it's sold."You don't want to listen to the people who are telling you with a hundred percent certainty, do this. And by the way, you know, buy my longevity latte."                                                    — Matt KaeberleinThey also compare LinAge2, a biological age calculator built from standard bloodwork with decades of mortality data behind it, to the consumer epigenetic age tests sold directly to the public. Kaeberlein's problem with the popular tests has nothing to do with the underlying science. It's that nobody selling them will publish the error bars, so a 20 year gap on your result could mean everything or nothing. You can't run statistics on a number you're not allowed to check.Along the way they cover why rapamycin, the drug most associated with Kaeberlein's name, might not even be his top pick anymore. A company spun out of his lab, Aura Biomedical, has found longevity molecules that also protect against radiation damage. And a new epigenetic instability test from Irena Conboy's company, Generation Lab, measures something closer to biological chaos than biological age.Follow The Daily Apple and leave a review to help more people find the show. Instagram: @KevinWhiteMDYouTube: @KevinWhiteMD Prime Health Associates

Up until just a couple years ago, an 85-year-old patient presenting with gradual, amnestic memory loss was almost automatically presumed to have Alzheimer's disease. However, new biomakers and the recognition of conditions like Limbic-predominant age-related TDP-43 encephalopathy (LATE) are reshaping our understanding of cognitive decline in older adults. It's looking more clear that pure Alzheimers dementia is rare in older adults, and co-occurring pathologies that may include Alzheimer's, LATE, Lewy Body, and vascular neuropatholigies, are the rule rather than the exception.  In this episode of the GeriPal Podcast, we sit down with Sterling Johnson and Nate Chin from the University of Wisconsin. Sterling is a clinical neuropsychologist and researcher who leads the CLARiTI study, which is attempting to uncover the intersecting causes of dementia.  Nate is the medical director and Clinical Core Co-Leader for the Wisconsin Alzheimer's Disease Research Center (ADRC), the host of the Dementia Matters podcast, and author of a new book When Memory Fades.   We tackle the real-world complexity of mixed dementia and its major diagnostic and clinical treatment dilemmas. We also go in deep to discuss LATE, from what it is, to how it presents, to whether it should change how we think about using newly approved disease-modifying therapies when a patient has confirmed amyloid positivity alongside suspected LATE.  

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Download the transcript here

Susan Wood, CEO of VIDA, develops AI-driven imaging-based biomarkers that quantitatively measure biological processes and disease states using imaging modalities such as CT, MRI, PET, and ultrasound. Unlike traditional visual image analysis, VIDA's technology extracts approximately 25,000 measurements per imaging timepoint, enabling detection of therapeutic responses at the sub-millimeter level. This convergence of advanced scanner technology, high-quality imaging data, and AI-powered analysis represents a significant new frontier in precision medicine and drug development. Susan explains, "I'll start with what VIDA brings in. Our background has been the development and validation of AI-driven imaging-based biomarkers. I'll start by defining a biomarker, specifically an imaging-based biomarker. It's a quantitative measurement derived from an imaging modality. An imaging modality can be a CT scan, an MRI, a PET scan, or an ultrasound, and the measurement reflects a biological process, a disease state, or a response to therapy. VIDA's formation was focused on the production and validation of those imaging-based biomarkers and on incorporating them into provider-based clinical workflows as well as clinical trial or drug development workflows." "I would say that in general, traditionally radiology has relied on radiologic images, those imaging modalities have been read visually. And if you read an image visually, there's just a fraction of information that you can get from those images versus reading them with these AI-generated processes. So there's less than 1% of that image you'll be able to understand the extent and the complexity of the measurements that image can offer. We read, or we combine that visual reading with a highly quantitative process. So for each imaging time point, we'll measure 25,000 measurements per imaging time point. Obviously that's well beyond what a human eye could do just from an efficiency standpoint, but certainly from a precision standpoint, they wouldn't be able to measure that level of precision in the imaging by an eyeball alone." #VIDA #AI #DigitalBiomarkers #MedicalImaging #Radiology #ClinicalTrials #DrugDevelopment #PrecisionMedicine #HealthcareInnovation #RespiratoryCare vidalung.ai Listen to the podcast here

Can advanced technology help us predict, prevent, and optimize our future health? In this episode, Dr. Adrijana Kekic, Founder and CEO of Futurome, explores how precision medicine, AI-driven insights, and advanced biological data are transforming the way we approach longevity. As a longevity pharmacist and expert in systems biology, Dr. Kekic helps executives, leaders, and high performers move beyond traditional health assessments by combining multiomics, digital biomarkers, pharmacogenomics, and personalized strategies designed to extend both lifespan and healthspan. In this conversation, we explore: ·       How multiomics reveals deeper insights into individual health and biology. ·       Why standard blood tests may miss important signals behind ongoing symptoms. ·       How pharmacogenomics helps predict individual responses to medications. ·       The role of AI, digital twins, and predictive health modeling in future medicine. ·       What cellular drift means and why detecting early changes matters. This episode offers a glimpse into the future of proactive healthcare—where personalized data, advanced technology and precision strategies help individuals take control of aging and long-term wellness. Connect with Dr. Adrijana Kekic and Futurome through their website, Instagram, LinkedIn and Youtube!. Episode also available on Apple Podcasts: https://apple.co/38oMlMr

Longevity expert Dr Florence Comite joins me to explain why testosterone, not estrogen, drives body composition and ageing in midlife women. Decline isn't inevitable - it's programmable. She unpacks why testosterone (which women carry in larger amounts than estrogen) drives muscle, visceral fat and brain fog from your 30s on, why only a third of us should fast, and the five biomarkers - fasting glucose, HbA1c, fasting insulin, cholesterol risk ratio and free testosterone - that predict where your healthspan is headed and how to change it. WHAT YOU'LL LEARN Why women carry more circulating testosterone than estrogen, and what its decline does to muscle, visceral fat and cognition from your 30s What "I don't feel like myself anymore" is actually signalling beneath the surface How cortisol quietly drives the anxiety-out-of-nowhere, the 2am wake-ups and the stubborn weight around your middle Why only a third of women should fast, and the 3-hour glucose test that tells you which third you're in What the five non-negotiable biomarkers reveal about where your healthspan is headed TIMESTAMPS 00:00 Intro: Why You Don't Feel Like Yourself After 35 - Peak Health, Testosterone Decline & the 30s Shift 05:52 - Perimenopause, Cortisol & Anxiety Out of Nowhere: Belly Fat, Sleep and the Caregiver Load 13:28 - Wearables, CGM & the Fasting Third/Third/Third: Measuring How Your Body Really Ages 20:11 - Who Should Actually Fast: The 3-Hour Glucose Test, Protein at Every Meal & the Oatmeal Trap 27:00 - Testosterone for Body Composition & Energy: UK Access, the 2024 Study & Protein for Muscle 33:46 - The 5 Biomarkers That Predict How You Age - Plus the 7 Patterns of Health Decline 39:37 - Decade by Decade for Women vs Men: Bone Loss, Osteoporosis, Andropause & Owning Your Healthspan VALUABLE RESOURCES - Invincible (Dr Comite's new book): https://www.penguin.co.uk/books/475986/invincible-by-comite-florence/9781529977066  - Dr Florence Comite's website: https://www.comitemd.com/  - Follow Dr Comite on Instagram: https://www.instagram.com/drflorencecomite/  AlgaeCal Plus*‡: Science-backed supplements designed to support healthy aging

Can a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Johnson & Johnson https://www.inlexzohcp.com/ --- Timestamps 00:00 - Introduction02:40 - Why Focus on TAR-20005:35 - Device Basics07:05 - Dosing Schedule Explained11:17 - SUNRISE-01 Trial Results15:07 - Patient Selection and Contraindications20:52 - Indications for Device Removal23:26 - Clinic Workflow Learning Curve25:56 - Tips for Insertion and Device Deployment28:52 - Cystoscopy Findings and Surveillance Protocol32:16 - Treatment Sequencing38:43 - Future Trial and Research Directions45:16 - Biomarkers, AI, and Personalizing Care46:35 - Cost, Supportive Care, and Patient Burden48:42 - Closing Thoughts --- More about this episode The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr. Psutka discusses dosing schedules, when to remove the device, and how to handle complications like UTI, hematuria, and LUTS. The episode also covers surveillance protocols, the impact on clinic operations, and the importance of balancing vigilant cancer surveillance with patient burden. Finally, they touch on future directions, including biomarkers, AI-assisted pathology, and optimizing the timing of cystectomy and supportive care for a more personalized approach to NMIBC. --- Resources TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Studyhttps://ascopubs.org/doi/10.1200/JCO-25-01651 SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-mushttps://www.urotoday.com/conference-highlights/suo-2024/suo-2024-bladder-cancer/156723-suo-2024-sunrise-5-a-phase-iii-randomized-open-label-study-of-tar-200-compared-with-intravesical-chemotherapy-after-bacillus-calmette-guerin-in-recurrent-high-risk-non-muscle-invasive-bladder-cancer.htmlcle Invasive Bladder Cancer Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Resultshttps://ascopubs.org/doi/10.1200/JCO-25-02382 INLEXZO - SunRISe-3 Studyhttps://www.jnjmedicalconnect.com/products/inlexzo/medical-content/inlexzo-sunrise-3-study --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Some of the best conversations don't happen on stage—they happen after the conference.Originally recorded following a previous Suisun Summit, this NeuroNoodle panel captures the discussions that were shaping the future of neurofeedback: biomarkers, QEEG, trauma, autism, ADHD, licensing, ethics, and why many clinicians are moving beyond diagnostic labels toward understanding brain function.With the 2026 Suisun Neuroscience Summit just around the corner, it's fascinating to revisit these conversations and see how many of these ideas continue to influence clinical practice today.

For decades, men with high-risk prostate cancer have routinely been told they need 18 to 36 months of androgen deprivation therapy (ADT) alongside radiation.But what if 12 months is enough?In this episode of the Dr. Geo Prostate Podcast, Dr. Geo Espinosa welcomes internationally recognized radiation oncologist Dr. Dan Spratt, Chair of Radiation Oncology at University Hospitals/Case Western Reserve University, to discuss groundbreaking research that could change how advanced prostate cancer is treated.Together they explore the latest MARCAP consortium data suggesting many men may receive the same cancer control with significantly less hormone therapy—potentially reducing years of unnecessary side effects while maintaining excellent outcomes. They also discuss how physicians personalize treatment decisions, the growing role of artificial intelligence with Artera AI, and why the future of prostate cancer treatment may involve doing less, not more.If you or someone you love is facing radiation therapy for prostate cancer, this episode provides one of the most important conversations happening in prostate cancer care today.What You'll Learn✔ Why 2-3 years of ADT may not be necessary for many patients✔ The new evidence supporting approximately 12 months of hormone therapy✔ Why longer hormone therapy can permanently affect testosterone recovery✔ How physicians balance cancer control with quality of life✔ The difference between NCCN guidelines and individualized patient care✔ Which patients may still benefit from longer hormone therapy✔ How AI (Artera AI) is helping personalize prostate cancer treatment✔ Why prostate cancer care is shifting toward treatment de-intensification✔ The future of precision medicine in radiation oncologyEpisode Timestamps00:00 Introduction01:30 Meet Dr Dan Spratt02:22 Why ADT Lasts Years05:42 How ADT Helps Radiation08:49 Personalizing ADT Duration12:39 Guidelines and Real World Use18:03 Who Needs Long Term ADT21:13 Artera AI Explained23:19 Old Data and Modern Outcomes27:28 De Intensification Future31:33 Biomarkers for Urologists33:57 Choosing Artera vs Decipher37:28 Final Takeaways and OutroKey Discussion PointsNew MARCAP consortium analysis on ADT durationRadiation sensitivity and androgen deprivationWhy many men never fully recover testosterone after prolonged ADTBalancing survival outcomes with quality of lifeShared decision-making between physician and patientGenomic classifiers including DecipherAI biomarkers and Artera AIPersonalized radiation oncologyModern imaging and PSMA PETDe-intensifying prostate cancer treatmentPrecision medicine in localized prostate cancerThe future of individualized prostate cancer careResources Mentioned• MARCAP Consortium research on androgen deprivation therapy duration• NCCN Prostate Cancer Guidelines (discussed throughout the episode)• Artera AI clinical decision support platform (discussion)• Decipher genomic classifier• PSMA PET imaging• MRI-guided prostate cancer staging___________________________________

Florence Comite, MD, a Yale-trained endocrinologist, precision-medicine pioneer, and author of Invincible, explains the five biomarkers that reveal how well you're aging and explores testosterone, metabolic health, cardiovascular risk, biological-age testing, sleep, fertility, and the early warning signs of future disease.This episode is proudly sponsored by:Jaspr is a powerful and beautiful at home air-scrubber that passively makes your home environment healthier by removing allergens, VOCs, dust, pollen, and more, from the air. Get $200 off each one you purchase at https://jaspr.co/genius using code GENIUS.I sleep on an Avocado mattress because real organic materials, no synthetic shortcuts, and better breathability make a noticeable difference. Go to ⁠http://avocadogreenmattress.com/MAX⁠ to check out their mattress and bedding sale.

I sat down with Dr. Jordan Metzl, a sports-medicine physician who's convinced that the reason most of us can't stay consistent isn't discipline or knowledge, it's motivation, and he says you can actually engineer it by "lowering the cost to act." We get into exercise as a literal medicine that would beat almost any drug if it came in a pill, why fun is the real holy grail of compliance, and how movement can go head-to-head with antidepressants for everyday anxiety and depression. If you've been white-knuckling your way through willpower and losing, this one's going to change how you think about getting off the couch. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Get Dr. Jordan Metzl's book, “Push: Unlock the Science of Fitness Motivation to Embrace Health and Longevity”: https://bit.ly/4f28xiO Connect with Dr. Jordan Metzl Website: https://bit.ly/4gzA0tp  Instagram: https://bit.ly/4aRhbhA  Facebook: https://bit.ly/4fdR45E  X: https://bit.ly/4aP5Mig   Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp CYMBIOTIKA: "ULTIMATE20" FOR 20% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TAB: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - ​Intro of Show 02:00 - From family of doctors to sports medicine 04:00 - Prescribing the medicine of exercise 05:55 - What an exercise prescription looks like 07:41 - The 1950s London Transport study 10:22 - Cellular adaptations and mitochondria 11:52 - Inflammation and chronic disease 13:31 - Immuno-fatigue and the theory of aging 14:45 - Motivation, not discipline, is missing 18:14 - Knowledge, emotion, and belief 20:25 - Building a fitness community 24:11 - Biomarkers and the cost of chronic disease 26:23 - Lifespan vs healthspan gap 28:26 - Fun is the holy grail of compliance 34:00 - Why remote work hurts our health 39:16 - Making exercise pay for doctors 41:01 - Two minutes of vigorous activity a day 44:30 - The GLP-1 and arthritic knee study 48:49 - Exercise vs antidepressants 55:38 - Lowering the cost to act 59:42 - What it means to be an Ultimate Human 1:01:29 - Alice: a marathon at 70 Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions.  Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and / or Gary Brecka directly or indirectly holds an economic interest or receives compensation.  Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this, our 331st Evolutionary Lens livestream, we discuss sunscreen and vegans. It's Summer, and the sun is out! Should you slather yourself in sunscreen, stay indoors, or seek moderate exposure to the sun that grows in intensity that more your skin becomes acclimated to the season? The last, of course. Research has found that sunscreen use may be positively correlated with skin cancer, but a) “sunscreen” is not just one thing, and most but not all sunscreen is positively toxic, and b) all cause mortality is lower in people who get regular (non-sunscreened) sun exposure, so even if sunscreen does lower your risk of skin cancer—the sun is protecting your health in other ways. Also consider ditching the sunglasses, and donning a hat. Then: even the New York Times can't figure out whose team they're on, as a vegan in Portland tries to get Oregonians to outlaw hunting, fishing, animal research, conventional livestock production, and “lethal pest control.”*****Our sponsors:Mud/WTR: Start your new morning ritual & get up to 43% off your @MUDWTR with code DarkHorse at http://mudwtr.com/DarkHorse #mudwtrpodCaraway: save up to $230 on the 12 piece cookware set vs buying the products individually; include minis duo & save up to $350. Visit http://Carawayhome.com/DarkHorse to take an additional 10% off using code DarkHorse on your next purchase.Puori: Clean and safe supplements, lab tested and guaranteed. Go to http://Puori.com/DarkHorse for 32% off grass-fed whey protein with a subscription. DarkHorse code works on all products!*****Join us on Locals! Get access to our Discord server, exclusive live streams, live chats for all streams, and early access to many podcasts: https://darkhorse.locals.comHeather's newsletter, Natural Selections (subscribe to get free weekly essays in your inbox): https://naturalselections.substack.comOur book, A Hunter-Gatherer's Guide to the 21st Century, is available everywhere books are sold, including from Amazon: https://amzn.to/3AGANGg (commission earned)Check out our store! Epic tabby, digital book burning, saddle up the dire wolves, and more: https://darkhorsestore.orgMusic: "Marble Machine" by WintergatanThis track can be downloaded for free at www.wintergatan.netFree License to use this track in your video can be downloaded at www.wintergatan.net*****Mentioned in this episode:Hulscher's substack: https://www.thefocalpoints.com/p/study-finds-sunscreen-use-linkedJeremian et al 2023. Gene–Environment analyses in a UK biobank skin Cancer cohort identifies important SNPs in DNA repair genes that may help prognosticate disease risk. Cancer Epidemiology, Biomarkers & Prevention, 32(11): 1599-1607: https://pmc.ncbi.nlm.nih.gov/articles/PMC10840669/pdf/nihms-1929398.pdfNicholson & Exley, C 2007. Aluminum: a potential pro-oxidant in sunscreens/sunblocks? Free Radical Biology and Medicine, 43(8): 1216-1217: https://www.ovid.com/journals/frbm/abstract/10.1016/j.freeradbiomed.2007.07.010~aluminum-a-potential-pro-oxidant-in-sunscreenssunblocksHunter-Gatherer's Guide: https://amzn.to/3AGANGg (commission earned)NYT in Oregon: https://www.nytimes.com/2026/06/21/us/politics/animal-rights-cruelty-oregon.htmlSupport the show